globalisation

Oncology

Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.

Oncology

The next leaders in oncology will be the ones built to adapt in real time.

R&D

Clinical trial expansion comes with complexity and increased risk, as each country has distinct regulatory requirements and contractual expectations.

Market Access

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

Oncology

At ESMO 2025 in Berlin, pharmaphorum spoke with Jo Feng, president of Hengrui Pharma.